Scarica l'app Stockscreener
1.22
2.78%
-0.04
Precedente Chiudi:
$1.26
Aprire:
$1.28
Volume 24 ore:
250.91K
Relative Volume:
0.65
Capitalizzazione di mercato:
$104.16M
Reddito:
$2.24M
Utile/perdita netta:
$-136.67M
Rapporto P/E:
-0.5622
EPS:
-2.17
Flusso di cassa netto:
$-102.08M
1 W Prestazione:
-2.78%
1M Prestazione:
-20.45%
6M Prestazione:
-58.75%
1 anno Prestazione:
-11.87%
Intervallo 1D:
$1.20
$1.28
Intervallo di 1 settimana:
$1.20
$1.31
Portata 52W:
$1.14
$5.51
Century Therapeutics Inc Stock (IPSC) Company Profile
Nome
Century Therapeutics Inc
Settore
Industria
Telefono
215-981-4000
Indirizzo
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Confronta IPSC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| IPSC | 1.225 | 104.16M | 2.24M | -136.67M | -102.08M | -2.17 |
| VRTX | 450.34 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.04 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.61 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.38 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-12-27 | Iniziato | Chardan Capital Markets | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-05-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-12 | Iniziato | William Blair | Mkt Perform |
| 2021-07-13 | Iniziato | BofA Securities | Buy |
| 2021-07-13 | Iniziato | JP Morgan | Overweight |
| 2021-07-13 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
Century Therapeutics Expands Clinical Focus and Reports Steady Financials for Q3 2024 - MSN
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire
Endo, Inc. Partners with MC2 Therapeutics to Bring Wynzora® Cream to Canadian Market - MyChesCo
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
Syncona Portfolio Ltd's Strategic Acquisition of Autolus Therape - GuruFocus.com
FMR LLC's Strategic Reduction in Century Therapeutics Inc Holdin - GuruFocus.com
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy - MyChesCo
Century Therapeutics to Present Cutting-Edge Preclinical Data at 2024 ASH Annual Meeting - MSN
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MyChesCo
William Blair Has Positive Estimate for IPSC FY2024 Earnings - Defense World
Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment - MyChesCo
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates - MSN
FY2024 Earnings Estimate for IPSC Issued By HC Wainwright - Defense World
Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances - MyChesCo
What Makes Century Therapeutics (IPSC) a New Buy Stock - Yahoo Finance
What is HC Wainwright's Forecast for IPSC FY2024 Earnings? - MarketBeat
William Blair Has Strong Estimate for IPSC FY2024 Earnings - MarketBeat
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo
Passage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference! - MyChesCo
Chardan Capital Has Lowered Expectations for Century Therapeutics (NASDAQ:IPSC) Stock Price - MarketBeat
Century Therapeutics, Inc. Demonstrates Strong Financial Management with No Senior Securities Defaults - TipRanks
Join Century Therapeutics at Guggenheim’s Healthcare Innovation Conference! - MyChesCo
Century Therapeutics shares target cut, retains Buy rating on updated data - Investing.com UK
HC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 - MarketBeat
Century Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Century Therapeutics COO sells $1,267 in stock - Investing.com
Century Therapeutics Reports Q3 Results & Strategic Updates - TipRanks
Century Therapeutics COO sells $1,267 in stock By Investing.com - Investing.com UK
Century Therapeutics earnings beat by $0.08, revenue topped estimates - Investing.com UK
InventHelp Inventor Develops Protective Accessory for Underwear (ASP-336) - Yahoo Finance
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times
Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting - The Manila Times
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of - The Bakersfield Californian
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting - Yahoo Finance
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025 - Yahoo Finance
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - The Manila Times
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference - GlobeNewswire
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo
We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate - Yahoo Finance
Context Therapeutics to Engage Investors at November Conferences - MyChesCo
electroCore (ECOR) Stock Jumps 11.7%: Will It Continue to Soar? - Yahoo Finance
Context Therapeutics to Showcase Promising Cancer Therapy at SITC Annual Meeting - MyChesCo
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 6.4% in September - MarketBeat
As the Cell Therapy Market Eyes $48 Billion, Bayer Invests $215 Million in Century Therapeutics As Revealed... - WhaTech
Dimensional Fund Advisors LP Acquires New Shares in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Artiva, Century, others extend natural-killer autoimmune push - BioWorld Online
Ubiquiti Inc. (NYSE:UI) Shares Sold by Dimensional Fund Advisors LP - Defense World
American Century Companies Inc. Has $128,000 Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Century Therapeutics Inc Azioni (IPSC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):